Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double…
Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer…
As of the data cutoff date, nine of the 14 evaluable patients treated with CUE-101+ KEYTRUDA® (pembrolizumab) demonstrated tumor regression,…
New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on…
Special Shareholder Meeting to be Held in July 2023PHILADELPHIA and VANCOUVER, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) -- BriaCell…
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., May 24,…
Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening SessionBOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --…
The Foundation will use H1’s Trial Landscape solution to streamline communication with physicians treating Parkinson’s, improve representation in clinical studies,…
TORONTO, May 24, 2023 (GLOBE NEWSWIRE) -- On May 28, Canadians coast to coast will come together to take part…
LANGHORNE, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of…